Oxaliplatin

• CAT Number: I013949
• CAS Number: 61825-94-3
• Molecular Formula: C₈H₁₄N₂O₄Pt
• Molecular Weight: 397.29
• Purity: ≥95%
• Target: Autophagy DNA Alkylator/Crosslinker
• Solubility: DMF: 17.5 mg/mL(Need ultrasonic and warming); H2O: 1.7 mg/mL (Need ultrasonic and warming)
• IUPAC Name: (1R,2R)-cyclohexane-1,2-diamine;oxalic acid;platinum
• InChI: InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/t5-,6-;;/m1../s1
• InChIKey: OGAPHRMCCQCJOE-BNTLRKBRSA-N
• SMILES: C1CCC(C(C1)N)N.C(=O)(C(=O)O)O.[Pt]

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts.

Reference

[1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71.[2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with cisplatin and carboplatin. Anticancer Drugs. 2000 Nov;11(10):859-63.[3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6.[4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604[5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43(4):237-50.[6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20.[7]. Romero HK, et al. Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1825-E1832.